Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

6.42
+1.9242.67%
Post-market: 6.39-0.0300-0.47%19:59 EDT
Volume:31.68M
Turnover:189.32M
Market Cap:297.40M
PE:-2.02
High:6.69
Open:5.28
Low:4.99
Close:4.50
Loading ...

Company Profile

Company Name:
4D Molecular Therapeutics
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
227
Office Location:
5858 Horton Street,Suite 455,Emeryville,California,United States
Zip Code:
94608
Fax:
- -
Introduction:
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Directors

Name
Position
David Kirn
Director and Chief Executive Officer
John F. Milligan
Executive Chairman of the Board
Charles Theuer
Independent Director
Jacob Chacko
Independent Director
Nancy Miller Rich
Independent Director
Shawn Cline Tomasello
Independent Director
Susannah Gray
Independent Director

Shareholders

Name
Position
David Kirn
Director and Chief Executive Officer
Fariborz Kamal
President and Chief Operating Officer
John F. Milligan
Executive Chairman of the Board
Noriyuki Kasahara
Chief Scientific Officer
Robert Young Kim
Chief Medical Officer
Scott Bizily
Chief Legal Officer and Corporate Secretary